

INFOGRAPHIC

Ingredients for a Deal-rich Year






What's the recipe for a deal-rich year in global biopharma R&D? A dash of growth, a generous amount of mid-size expansion, equal portions of internal and external innovation, and a pinch of positivity.

Global Biopharma R&D Pipeline

Total size has grown by 7.2%; 22,825 drugs under development




continues its rise

Biopharma R&D

- Considerable attrition within pipeline as it renews
- **R&D** universe breaks 6,000-company threshold

Global Biopharma R&D Pipeline

Large pharma share diminishes; expansion driven by mid-size companies



Portfolios generally align to 50:50 internal vs. external innovation


Large Pharma R&D Strategy

balanced with external innovation The largest pipelines

pharmas are well

Majority of big






Industry Patent Cliff and Growth Gap

cliff approaching Sales at risk from patent expiration 120 8%

More than \$200bn of industry revenues entering loss of exclusivity crosshairs



Business development critical to replace

lost revenues


Significant patent

Bolt-on acquisitions of R&D-stage biotechs have

become essential 45

50

- Financial firepower remains at record levels



R&D-stage biopharma M&As

To learn more about the advantages we can deliver to your company, please visit: Citeline.com or email: info@Citeline.com

Copyright © 2023 Pharma Intelligence UK Limited (Citeline), a Norstella company. Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB









20

CITELINE.COM